← Back
Data updated: Mar 29, 2026
CYCLE
OncologyNeurologyCardiovascular
Generics
CYCLE is a generic drug manufacturer focused on Oncology, Neurology, Cardiovascular. Key products include TASCENSO ODT.
1975
Since
11
Drugs
-
Trials
54
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
CHLORPROMAZINE HYDROCHLORIDE 2026-01-26
CHLORPROMAZINE HYDROCHLORIDE 2025-10-10
PIROXICAM 2025-09-12
Labeling
QUINIDINE SULFATE 2025-08-21
Labeling
QUINIDINE SULFATE 2025-07-29
Labeling
INDOMETHACIN 2025-07-03
HARLIKU 2025-06-10
Efficacy
INDOMETHACIN 2025-06-02
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 42%
0 drugs Phase 2: 4 Phase 1: 3
Neurology 23%
1 drugs
Cardiovascular 15%
0 drugs Phase 2: 2
Metabolic 15%
0 drugs Phase 2: 2
Gastroenterology 4%
0 drugs Phase 1: 1
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Takeda big-pharma
Oncology, Gastroenterology, Neurology, Metabolic
Merck big-pharma
Oncology, Cardiovascular, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Cardiovascular, Neurology
Johnson & Johnson big-pharma
Oncology, Cardiovascular, Metabolic
Amgen biotech
Oncology, Metabolic, Gastroenterology, Neurology
Active (3)
Discontinued (8)
Company Info
- First Approval
- 1975-07-15
- Latest
- 2025-06-10
- Applications
- 13